{"id":"f3c5cb01-4097-5d02-b1c5-1c97b4881c89","stable_key":"c836a883-ac18-5eb2-9971-2f0b542feba8:age-cac","predicate":"decreases_in_recorded_experiment","statement":"The European AGE trial reported lower coronary calcium-score progression than placebo over one year.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"17558ce0-6cb0-5d69-9c23-f443d53944df","mechanism_event_label":"The European AGE trial reported lower coronary calcium-score progression than placebo over one year.","subject":{"id":"d7670c3d-c275-5413-895a-53b1b7567ddd","slug":"aged-garlic-wlosinska-2020","display_name":"Aged garlic extract in the European 2020 coronary-calcium trial","entity_type_key":"botanical"},"object":{"id":"54a7068f-5950-585a-b82a-006bbf340dea","slug":"human-age-coronary-calcium-progression","display_name":"Coronary calcium-score progression in the aged garlic trial","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"17558ce0-6cb0-5d69-9c23-f443d53944df","stable_key":"c836a883-ac18-5eb2-9971-2f0b542feba8:age-cac-event","event_type":"experimental_observation","label":"The European AGE trial reported lower coronary calcium-score progression than placebo over one year.","description":"**Coronary imaging.** A European trial randomized 104 participants to 2.4 g/day aged garlic extract or placebo for one year; ninety-three were analyzed. It reported lower coronary-calcium progression with the extract. It was retrospectively registered and received manufacturer funding and product support alongside other funding. Coronary calcium progression is an imaging outcome, not proof of plaque reversal, fewer infarctions, or allicin target engagement. It must remain distinct from low-attenuation plaque and total plaque-volume measurements. [Wlosinska 2020](https://pmc.ncbi.nlm.nih.gov/articles/PMC7191741/)","status":"provisional","compartment":null,"participants":[{"entity":{"id":"d7670c3d-c275-5413-895a-53b1b7567ddd","slug":"aged-garlic-wlosinska-2020","display_name":"Aged garlic extract in the European 2020 coronary-calcium trial","entity_type_key":"botanical"},"role":"tested factor","stoichiometry":null,"state_label":"Specified aged garlic extract","sequence_order":0,"notes":""},{"entity":{"id":"54a7068f-5950-585a-b82a-006bbf340dea","slug":"human-age-coronary-calcium-progression","display_name":"Coronary calcium-score progression in the aged garlic trial","entity_type_key":"cellular_process"},"role":"measured outcome","stoichiometry":null,"state_label":"decrease","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary full text available; selected claim-relevant methods, results, tables/figures and limitations reviewed. Supplemental proteome and all secondary findings are not exhaustively extracted.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"Specified aged garlic extract\", \"comparator\": \"Placebo\", \"endpoint\": \"The European AGE trial reported lower coronary calcium-score progression than placebo over one year.\", \"effect_direction\": \"decrease\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; source-derived draft.","entity":null},{"dimension":"experimental_model","value_text":"104 randomized, 93 analyzed; 2.4 g/day AGE; baseline-adjusted analyses of imaging progression.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Retrospective trial registration, baseline imbalances and manufacturer support; surrogate imaging outcome, not plaque reversal or fewer cardiovascular events.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The European AGE trial reported lower coronary calcium-score progression than placebo over one year.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"The effect of aged garlic extract on the atherosclerotic process - a randomized double-blind placebo-controlled trial. | 2020 | DOI 10.1186/s12906-020-02932-5 | PMID 32349742 | https://pubmed.ncbi.nlm.nih.gov/32349742/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC7191741/ | https://doi.org/10.1186/s12906-020-02932-5","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference lines 93-93; exact primary location described in quoted passage where extracted.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"feeb3f6d-3eed-59df-8e7e-7cda802a0ea6","evidence_kind":"source_excerpt","locator":"Lines 93-93","start_line":93,"end_line":93,"excerpt":"**Coronary imaging.** A European trial randomized 104 participants to 2.4 g/day aged garlic extract or placebo for one year; ninety-three were analyzed. It reported lower coronary-calcium progression with the extract. It was retrospectively registered and received manufacturer funding and product support alongside other funding. Coronary calcium progression is an imaging outcome, not proof of plaque reversal, fewer infarctions, or allicin target engagement. It must remain distinct from low-attenuation plaque and total plaque-volume measurements. [Wlosinska 2020](https://pmc.ncbi.nlm.nih.gov/articles/PMC7191741/)","model_system":"104 randomized, 93 analyzed; 2.4 g/day AGE; baseline-adjusted analyses of imaging progression.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Exact excerpt of the retained AI-assisted reviewed reference; primary sources are cited in primary_references and access scope is retained. Not a verbatim quotation from a primary paper.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"10820a6b-594a-547d-97f9-906ab4cc1d6e","stable_key":"import-c836a883-ac18-5eb2-9971-2f0b542feba8","title":"Allicin: detailed mechanisms of action (reviewed 5 October 2026)","document_type":"imported_text","citation_label":"Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication.","file_path":"","sha256":"2475d3eb681100a0a34577a47b7cba5b251df866fbd6ce795122ccabee360018","revision_id":"590df96d-2ed1-5763-b04c-bf0e096e603c","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}